Universal, stage-agnostic molecular profiling in NSCLC is increasingly necessary, as under-testing (including absent RNA fusion panels) can misdirect immunotherapy use in EGFR/ALK-altered disease.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment. Comprehensive biomarker testing in ...

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic counseling and ...

Despite broader guidelines and life-saving targeted therapies, real-world evidence reveals persistent gaps and inequities in BRCA testing, raising urgent questions about who gets access to precision ...

When someone is diagnosed with cancer, time matters. Patients and their families are often forced to make urgent, life-altering decisions while navigating fear, uncertainty and a complex health care ...

For most of the last century, getting a blood test meant one thing: a doctor had to order it. You needed an appointment, a referral, an insurance pre-authorization, and then you waited, sometimes ...